Menu

Home
About Us
Products
Seminars
Hospitals
Resources
Ed4StudentNurses
Coaching4Nurses
2 Minute EBP Challenge
Articles
Ed4Nurses LIVE
FAQs
Inspiration
See Us On YouTube
Nurses Success Network

Search

 

2 Minute EBP Challenge

Monday, January 30, 2012
Scrub the Hub
The Centers for Disease Control (CDC) recommends that central venous catheter (CVC) hubs be scrubbed for how long?

Monday, January 23, 2012
Severe Sepsis and AF Risk
Up to 20% of patients with severe sepsis develop a new onset atrial fibrillation.  Which factor was not associated with increased risk?

Monday, January 16, 2012
Unreported Hospital Errors
In a recent study the Department of Health and Human Service reports that what percentage of hospital errors go unreported?

Subscribe
  
Archives
<February 2012>
>>SunMonTueWedThuFriSat
>2930311234
>567891011
>12131415161718
>19202122232425
>26272829123
>45678910
Categories


  • Get tips, timesavers, and more from
    David W. Woodruff, MSN, RN-BC, CNS, CMSRN, CEN

    Heparin-induced Thrombocytopenia

    Monday, January 25, 2010

    Stay up-to-date the easy way!

    How would you answer this question?


    Your patient Mr. Kellogg is diagnosed with heparin-induced thrombocytopenia (HIT).  As his nurse you should anticipate that his physician will treat HIT with:

    a. Platelet transfusions
    b. Warfarin
    c. Argatroban
    d. Enoxaparin

    The correct answer is "c" argatroban.

    Thrombocytopenias are a collection of conditions that cause the platelet count to decrease.  There are many ways that platelets can become activated and depleted in the clotting process.  The most common reasons for drops in platelet counts are depletion from pre-existing conditions such as sepsis, trauma, or surgery.  Approximately 5% of patients that receive heparin will develop an immune response that activates platelets causing life-threatening clotting and occasional bleeding.  This condition is called heparin-induced thrombocytopenia.

    Heparin is a drug that inhibits platelets from forming clots by inactivating thrombin and depressing platelet function directly.  The result is a decrease in clot formation and increased bleeding.  Preventing clot formation is beneficial in your patient with a pulmonary embolism or myocardial infarction, but adverse effects can occur such as intracranial hemorrhage with the use of heparin.

    A small percentage of the population will develop an immune response to heparin that leads to activation of platelets, rather than inhibition.  This condition is referred to as heparin-induced thrombocytopenia (HIT), and results in the activation and depletion of platelets in the presence of therapeutic doses of heparin.

    The most effective way to treat HIT is to discontinue all forms of heparin, including IV flushes.  Administering platelets to this patient can cause more clotting and increase the severity of symptoms.  Enoxaparin is a low-molecular weight heparin that can cause HIT, and warfarin can cause tissue necrosis in HIT.  Argatroban is an anticoagulant that will not worsen HIT.  Argatroban works by directly inhibiting thrombin and not by stimulating heparin antibodies, and is therefore safe in treating HIT.

    From:  Woodruff, D.W. (2006). HIT: Now you see 'em , now you don't.  Nursing Made Incredibly Easy, 4(1); 53-55.

    Congratulations to Toronda Jones-Hickson who won an autographed copy of my 101 Tips to Improve Your Nursing Care book for answering this week's question correctly.  Congratulations Toronda!    


    Best wishes,
    David W. Woodruff, MSN, RN-BC, CNS, CEN
    President,
    Ed4Nurses, Inc.

    (c) 2010 Ed4Nurses, Inc.  Feel free to print this e-mail and share it with your colleagues. Other forms of digital or print reproduction are prohibited without prior written consent from Ed4Nurses, Inc.
    Print this page